Cerebrolysin
Also known as cerebral peptides · porcine brain peptide mixture
Porcine neuropeptide mixture used in some international stroke and cognition programs, but not FDA-approved.
Clinical Stage
This is a clinical-stage therapeutic, not a typical consumer RUO product. Information is provided for educational context about ongoing clinical research.
Evidence visual
Cerebrolysin evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
medium
Regulatory
not approved
WADA
none
FDA
unknown
Route
intravenous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Cerebrolysin is not a single peptide but a porcine-derived neuropeptide mixture used in some countries for stroke and cognitive recovery. Evidence quality is mixed and product standardization is harder to assess than for single-molecule peptides. It should be treated as an advanced neurorecovery compound with limited relevance to casual nootropic use.
Decision path
Where Cerebrolysin fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Cerebrolysin belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Proposed neurotrophic and neuroprotective signaling from a peptide/amino-acid mixture; exact active components remain poorly defined.
intravenous, intramuscular
Clinical programs often use 5 mL to 30 mL IV daily over 10 to 20 days depending on indication.
Possible neurorecovery or cognitive-support effects in select clinical settings, though evidence quality is heterogeneous.
Clinical outcomes are tracked over days to weeks in stroke or cognition programs.
Use caution in porcine-protein sensitivity and where product provenance cannot be established.
Headache, fever, nausea, restlessness, injection reactions, and rare hypersensitivity are reported.
No strong interaction map; combining with other CNS-active research compounds increases interpretation difficulty.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Cerebrolysin.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.